Vaccines against varicella-zoster virus;Vacunas frente al virus de la varicela zóster

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 26, Issue SUPPL. 1, 2008, Pages 29-47

  Salleras Sanmartí, Luis ^a,c   Redonnet, Monserrat Salleras ^b   Prat, Andrés ^a   Garrido, Patricio ^a   Domínguez, Ángela ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARI SAGRAT COR   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Herpes zoster; Vaccine; Varicella

Indexed keywords

CHICKENPOX VACCINE; VARICELLA ZOSTER VACCINE;

DRUG EFFICACY; HERPES ZOSTER; HOSPITALIZATION; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INFECTION SENSITIVITY; POSTHERPETIC NEURALGIA; PREVALENCE; REVIEW; VARICELLA ZOSTER VIRUS; VIRUS REACTIVATION;

EID: 44949257268     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/s0213-005x(08)76223-2     Document Type: Review

References (154)

1. Weller TH. Varicella and herpes zoster: changing concepts of the natural history, control, and importance of a not-so-benign virus. N Engl J Med. 1983;309:1434-40.
2. Gnann JW Jr, Whitley RJ. Hespes zoster. N Engl J Med. 2002;347:340-6.
3. Hope-Simpso RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med. 1965;58:9-20.
4. Holodniy M. Prevention of shingles by varicella zoster virus vaccination. Expert Rev Vaccines. 2006;5:431-43.
5. Gershon AA, Takahashi M, Seward J. Varicella vaccine. En: Plotkin SA, Orenstein WA, editors. Vaccines. 4th ed. Philadelphia: WB Saunders; 2004. p. 783-824.
6. Arvin A. Aging, immunity and the varicella-zoster virus. N Engl J Med. 2005;352:2266-7.
7. Hayward A, Levin M, Wolf W, Angelova G, Gilden D. Varicella-zoster viruse-specific immunity after herpes zoster. J Infect Dis. 1991;163:873-5.
8. Arvin AM. Cell-mediated immunity to varicella-zoster virus. J Infect Dis. 1992;166 Suppl 1:35-41.
9. Ku CC, Besser J, Aberdroth A, Grose C, Arvin AM. Varicella-Zoster virus pathogenesis and immunobiology: new concepts emerging from investigations with the SCIDhu mouse model. J Virol. 2005;79:2651-8.
10. Brisson M, Gay N, Edmunds WJ, Andrews NJ. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine. 2002;20:2500-7.
11. Thomas S, Wheeler J, Hall AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet. 2002;360:678-82.
12. Miller AE. Selective decline in cellular immune response to varicella-zoster in the elderly. Neurology. 1980;30:582-7.
13. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271-84.
14. Gilden DH. Varicella-zoster virus vaccine. Grown-ups need it, too. N Engl J Med. 2005;352:2344-6.
15. Gershon AA. Varicella-zoster virus: prospects for control. Advances in pediatric infectious diseases. Mosby Year Book. 1995;10:93-124.
16. a ed. Barcelona: Masson; 2003; p. 311-30.
17. Wharton M. The epidemiology of varicella-zoster virus infection. Infect Dis Clin North Am. 1996;10:571-581.
18. Hambleton S, Gershon AA. Preventing varicella-zoster disease. Clin Microbiol Rev. 2005;18:70-80.
19. Salleras L, Salleras M, Domínguez A, Prat A, Navas E. Varicela en el adolescente y adulto. Carga de la enfermedad y potencial de prevención mediante la vacunación. Vacunas. 2005;6:92-106.
20. Salleras L, Domínguez A, Vidal J, Plans P, Salleras M, Taberner JL. Seroepidemiology of varicella-zoster virus infection in Catalonia (Spain). Rationale for universal vaccination programmes. Vaccine. 2001;19:183-8.
21. La Russa P. Clinical manifestations of varicella. En: Arvin AM, Gershon AA, editors. Varicella-zoster virus. Cambridge: Cambridge University Press; 2000; p. 206-19.
22. Danovaro-Holliday MC, Gordon ER, Jumaan AO, Woernle C, Judy RH, Scott Schmid D, et al. High rate of varicella complications among mexican-born adults Alabama. Clin Infect Dis. 2004;39:1633-9.
23. Feldman S, Hughes W, Daniel C. Varicella in children with cancer: 77 cases. Pediatrics. 1975;80:388-97.
24. Watson BH, Foster JA, White CJ, Laufer D. Varicella in the normal and immunocompromissed host. Bailliere's Clin Infect Dis.1996;3:425-38.
25. Enders G, Miller E. Varicella and herpes zoster in pregnancy and the new-born. En: Arvin AM, Gershon AA, editors. Varicella-zoster virus. Cambridge: Cambridge University Press; 2000. p. 206-19.
26. Coplan P, Black S, Rojas C, Shinefield H, Ray P, Lewis E, et al. Incidence and hospitalization rates of varicella and herpes zoster before varicella vaccine introduction: a baseline assessment of the shifting epidemiology of varicella disease. Pediatr Infect Dis J. 2001;20:641-5.
27. Davis MM, Patel MS, Gebremariam A. Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States. Pediatrics. 2004;114:786-92.
28. Gil A, González A, Oyáguez I, San-Martín M, Carrasco P. The burden of severe varicella in Spain, 1995-2000 period. Eur J Epidemiol. 2004;19:699-702.
29. Gil A, San-Martín M, Carrasco P, González A. Epidemiology of severe varicella-zoster virus infection in Spain. Vaccine. 2004;22:3947-51.
30. Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med. 2005;352:450-8.
31. Tsolia M, Gershon AA, Steinberg SP, Gelb L. Live attenuated varicella vaccine: Evidence that the virus is attenuated and the importance of the skin lesions in transmission of varicella-zoster virus. J Pediatr. 1990;116:184-9.
32. André FE. Summary of clinical studies with the OKA live varicella vaccine produced by Smith Kline-RIT. Biken J. 1984;27:89-98.
33. Product Monograph Varilrix®. GlaxoSmithKline. September 12, 2002.
34. Salleras L, Moraga F, Salleras M, Domínguez A, Prat A. Inmunogenicidad y eficacia protectora de la vacuna de la varicela atenuada y efectividad e impacto de la vacunación universal de la población infantil. Vacunas. 2006;7:168-80.
35. Ellis RW. Varicella vaccine. Vaccine. 1995;13:1387-8.
36. Product Monograph Varivax® III. Merck Frosst Canada and CO. March 14, 2003.
37. Kraiouchkine N, Shaw AR, Keller PM, Distefano DJ. Comparison of the complete genome sequences of varicella zoster virus Oka/Merck (Varivax) and Oka/GSK (Varilrix). In 43rd Interscience Conference on Antimicrobial Agents and Quemotherapy; september 14-17, 2003 [abstract 6-1652]. Chicago, Washington DC. American Society for Microbiology.
38. Gershon AA. Human immune responses to live attenuated varicella vaccine. Rev Infect Dis. 1991;13 Suppl 11:957-9.
39. Provost PJ, Krah DL, Kuter BJ, et al. Antibody assays suitable for assessing immune responses to live varicella vaccine. Vaccine. 1991;9:111-6.
40. Wasmuth EH, Miller WJ. Sensitive enzyme-linked immunosorbent assay for antibod to varicella zoster virus using purified VZV glycoprotein antigen. J Med Virol. 1990;32:189-93.
41. Watson B, Boardman C, Laufer D, Piercy S, Tustin N, Olaleye D, et al. Humoral and cell mediate immune responses in healthy children after one or two doses of varicella vaccine. Clin Infect Dis. 1995;20:316-9.
42. Gershon AA, LaRussa P, Hardy I, Steinberg S, Silverstein R. Varicella vaccine: the American experience. J Infect Dis. 1992;166 Suppl:63-8.
43. White CJ, Kuter BJ, Hildebrand CS, Isganitis KL, Matthews H, Miller WJ, et al. Varicella vaccine (Varivax) in healthy children and adolescents. Results froma clinical trails, 1987 to 1989. Pediatrics. 1991;87:604-10.
44. Weibel RE, Neff BJ, Kuter BJ, Guess HA, Rothenberger CA, Fitsgerald AJ, et al. Live attenuated varicella vaccine: efficacy trial in healthy children. N Engl J Med. 1984;310:1409-15.
45. Kuter BJ, Weibel RE, Guess HA, Mathews H, Morton DM, Neff BJ, et al. Oka/Merk varicella vaccine in healthy children: final report of a 2-year efficacy stydy and 7-year follow up studies. Vaccine. 1991;9:643-7.
46. Arbeter AM, Starr SE, Plotkin SA. Varicella vaccine studies in healthy children and adults. Pediatrics. 1986;78 Suppl:748-56.
47. Arbeter AM, Starr SE, Preblud SR, Ihara T, Paciorek PM, Miller DS, et al. Varicella vaccine trials in healthy children: a summary of comparative an follow-up studies. Am J Child. 1984;138:434-8.
48. Johnson CE, Shurin PA, Fattlar D, Rome LP, Kumar ML. Live attenuated varicella vaccine in healthy 12-to 24-month-old children. Pediatrics. 1988;81:512-8.
49. Weibel RE, Kuter BJ, Neff BJ, Rothenberger LA, Fitzgerald AJ, Connor KA, et al. Live OKA/Merck varicella vaccine in healthy children: further clinical and laboratory assessment. JAMA. 1985;254:2435-9.
50. White CJ. Clinical trials of varicella vaccine in healthy children. Infect Dis Clin North Am. 1996;10:595-607.
51. Meurice F, De Bouver JL, Vandevoorde D, Woods S, Bogaerts H. Immunogenicity and Safety of a Live Attenuated Varicella Vaccine (OKA/SB Bio) in Healthy Children. J Infect Dis. 1996;174 Suppl 3:324-9.
52. Just M, Berger R, Luescher D. Live varicella vaccine in healthy individuals. Postgrad Med J. 1985;61 Suppl 4:129-32.
53. André FE. Summary of clinical studies with the OKA live varicella vaccine produced by Smith Kline-RIT. Biken J. 1984;27:89-98.
54. Ramkisoon A, Coovadia HM, Yugnundan P, Haffejer IE, Meurice F, Vandervoorde D. Immunogenicity and safety of a live attenuated varicella vaccine in healthy Indian children aged 9-24 months. S Afr Med J. 1995;85:1295-8.
55. Tan AYS, Connett CJ, Connett GJ, Quek SC, Yap HK. Use of reformulated OKA Strain varicella vaccine (SKB/OKA) in healthy children. Eur J Pediatr. 1996;155:706-11.
56. Varis T, Vesikari T. Efficacy of high-titer attenuated varicella vaccine in healthy young children. J Infect Dis. 1996;174 Suppl 3:330-4.
57. Lau YL, Vessey SJ, Chan IS, Lee TL, Huang LM, Lee CY. A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and Varilrix in healthy children. Vaccine. 2002;20:2942-9.
58. Arberter AM. Clinical trials of varicella vaccine in healthy adolescents and adults. Infect Dis Clin North Am. 1996;10:609-15.
59. Gershon AA, Steinberg SP, LaRussa P, Ferrara A, Hammerschlag M, Gelb L. Immunization of healthy adults with live attenuatd varicella vaccine. J Infect Dis. 1988;158:132-7.
60. Ndumbe PM, Cradock-Watson JR, Mac Queen S, Dunn H, Andre F, Davis EG, et al. Immunization of healthy adults with live attenuated varicella vaccine. J Infect Dis. 1992;165:852-8.
61. Barzaga NC, Florece RH, Bock HL. Reactogenicity and immunogenicity of a varicella vaccine in Healthy seronegative and seropositive subjects. South East Asian J Trop Med Public Health. 2002;33:259-67.
62. Tlesnik V, Prikazsky V, Petvaldsk L. Protective effect of vaccination against chickenpox. Epidemiol Mikrobiol Imunol. 2000;49:143-7.
63. Kusowon P, Sutra S, Kosalaraska P. Advantage of a two-dose versus one dose varicella vaccine in healthy non-immune teeangers and young adults. Southeast Asian J Trop Med Public Health. 2004;35:697-701.
64. a ed. Barcelona: Masson; 2003.
65. Clements DA, Moreira SP, Coplan PM, Bland CL, Walter EB. Postlicensure study of varicella vaccine effectiveness in a day care setting. Pediatric Infect Dis J. 1999;18:1047-50.
66. Vázquez M, La Russa PS, Gershon AA, Steinberg SP, Freudingman K, Shapiro ED. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med. 2001;344:955-60.
67. Vázquez M, LaRussa PS, Gershon AA, Niccolai LM, Muehlenbein CE, Steinberg SP, et al. Effectiveness over time of varicella vaccine. JAMA. 2004;291:851-5.
68. Seward JF, Zhang JX, Maupin TJ, Mascola L, Jumaan AO. Contagiousness of varicella in vaccinated cases: a household contact study. JAMA. 2004;292:704-8.
69. Passwell JH, Hemo B, Levi Y, Ramon R, Friedman N, Lerner-Geva L. Use of a computerized database to study the effectiveness of an attenuated varicella vaccine. Pediatr Infect Dis J. 2004;23:221-6.
70. Sheffer R, Segal D, Rahamani S, Dalal I, Linhart Y, Stein M, et al. Effectiveness of the Oka/GSK attenuated varicella vaccine for the prevention of chickenpox in clinical practice in Israel. Pediatr Infect Dis J. 2005;24:434-7.
71. Izurieta HS, Strebel PM, Blake PA. Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center. JAMA. 1997;278:1495-9.
72. Galil K, Fair E, Mountcastle N, Britz P, Seward J. Yonger age at vaccination may increase risk of varicella vaccine failure. J Infect Dis. 2002;186:102-5.
73. Galil K, Lee B, Strine T, Carraher C, Baughman AL, Eaton M, et al. Outbreak of varicella at a day-care center despite vaccination. N Engl J Med. 2002;347:1909-15.
74. Tugwell BD, Lee LE, Lorber K, Gillette H, Lorber EM, Hedberg K, et al. Chickenpox outbreak in a highly vaccinated school population. Pediatrics. 2004;113:455-9.
75. Buchholz U, Moolenaar R, Peterson C, Mascola L. Varicella outbreaks after vaccine licensure: should they make you chicken? Pediatrics. 1999;104:561-3.
76. Dworkin MS, Jennings CE, Roth-Thomas J, et al. An outbreak of varicella among children attending preschool and elementary school in Illinois. Clin Infect Dis. 2002;35:102-4.
77. Lee BR, Feaver SL, Miller CA, Hedberg CW, Ehresmann KR. An elementary school outbreak of varicella attributed to vaccine failure: policy implications. J Infect Dis. 2004;190:477-83.
78. Marin M, Nguyen HQ, Keen J, Jumaan AO, Mellen PM, Hayes EB, et al. Importance of catch-up vaccination: experience from a varicella outbreak, Maine, 2002-2003. Pediatrics. 2005;115:900-5.
79. Haddad MB, Hill MB, Pavia AT, Green CE, et al. Vaccine effectiveness during a varicella outbreak among schoolchildren: Utah, 2002-2003. Pediatrics. 2005;115:1488-93.
80. Miron D, Lavi I, Kitov R, Hendler A. Vaccine effectiveness and severity of varicella among previously vaccinated children during outbreaks in day-care centers with low vaccination coverage. Ped Infect Dis J. 2005;24:233-6.
81. López AS, Guris D, Zimmerman L, Gladden L, Moore T, Haselow DT, et al. One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose? Pediatrics. 2006;117:1070-7.
82. Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T, Isomura S. Live vaccine used to prevent.the spread of varicella in children in hospital. Lancet. 1974;2:1288-90.
83. Naganuma Y, Osawa S, Takahashi R. Clinical application of a live varicella vaccine (OKA strain) in a hospital. Biken J. 1984;27:59-61.
84. Asano Y, Nakayama H, Yazaki T, Ito S, Isomura S, Takahashi M. Protective efficacy of vaccination in children in four episodes of natural varicella and zoster in the ward. Pediatrics. 1977;59:8-12.
85. Asano Y, Yazaki T, Miyata T, Nakayama H, Hirose S. Application of a live attenuated varicella vaccine to hospitalized children and its protective effect on spread of varicella infection. Biken J. 1975;18:35-40.
86. Asano Y, Iwayama S, Miyata T, Yazaki T, Ozaki T, Tsuzuki K, et al. Spread of varicella in hospitalized children having no direct contact with an indicator zoster case and its prevention by a live vaccine. Biken J. 1980;23:157-61.
87. Katsushima N, Yazaki N, Sakamoto M, Fujiyama J, Nakagawa M, Okuyama Y, et al. Application of a live varicella vaccine to hospitalized children and its follow-up study. Biken J. 1982;25:29-42.
88. Katsushima N, Yazaki N, Sakamoto M. Effect and follow-up study on varicella vaccine. Biken J. 1984;27:51-8.
89. Salzman MB, García C. Postexposure varicella vaccination in siblings of children with active varicella. Pediatr Infect Dis J. 1998;17:256-7.
90. Watson B, Seward J, Yang A, Witte P, Lutz J, Chan C, et al. Postexposure effectiveness of varicella vaccine. Pediatrics. 2000;105:84-8.
91. CDC. Prevention of varicella. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1996;45:1-36.
92. CDC. Prevention and control of varicella. MMWR. 1999;48:1-6.
93. Seward KF, Watson BM, Peterson CL, Mascola L, Pelosi JW, Zhang JX, et al. Varicella disease after the introduction of varicella vaccine in the United States 1995-2000. JAMA. 2002;287:606-11.
94. Quian J, Romero C, Dalorso P, Cerisola A, Rüttimann R. Resultados de la vacunación universal a niños de un año con vacuna de la varicela en Montevideo, Uruguay. Arch Ped Urug. 2003;74:259-67.
95. Mullooly JP, Maher JE, Drew L, Schuler R, Hu W. Evaluation of the impact of an HMO's varicella vaccination program on incidence of varicella. Vaccine. 2004;22:1480-5.
96. Centers for Disease Control and Prevention (CDC). Decline in annual incidence of varicella: selected states, 1990-2001. MMWR. 2003;52:884-5.
97. Seward JF. Update on varicella. Ped Infect Dis J. 2001;20:619-21.
98. Vázquez M. Varicella infections and varicella vaccine in the 21st century. Pediatr Infect Dis J. 2004;23:871-2.
99. Zhou F, Harpaz R, Jumaan AO, Winston CA, Shefer A. Impact of varicella vaccination on health care utilization. JAMA. 2005;294:797-802.
100. Staat MA, Meinzen-Derr J, Welch T, Roberts NE, Jamison L, Gerber MA, et al. Varicella-related hospitalization and emergency department visit rates, before and after introduction of varicella vaccine, among white and black children in Hamilton County, Ohio. Pediatrics. 2006;117:833e-9e.
101. Chant KG, Sullivan EA, Burgess MA, Ferson MJ, Forrest JM, Baird LM, et al. Varicella-zoster virus infection in Australia. Aust N Z J Public Health. 1998;22:413-8. Erratum in: Aust N Z J Public Health. 1998;22:630.
102. Lam MS, Chew SK, Allen DM, Monterio EH. Fatal varicella infections in Singapore. Singapore Med J. 1993;34:213-5.
103. Bramley JC, Jones IG. Epidemiology of chickenpox in Scotland: 1981 to 1998. Commun Dis Public Health. 2000;3:282-7.
104. Boelle PY, Hanslik T. Varicella in non-immune persons: incidence, hospitalization and mortality rates. Epidemiol Infect. 2002;129:599-606.
105. Fairley CK, Miller E. Varicella-zoster virus epidemiology: a changing scene? J Infect Dis. 1996;174 Suppl 3:314-9.
106. Rawson H, Crampin A, Noah N. Deaths form chickenpox in England and Wales 1995-7: analysis of routine mortality data. BMJ. 2001;323:1091-3.
107. Quian J, Dall'Orso P, Romero C, Cerisola A, Protasio A. Análisis de los resultados de la inmunización universal a los 12 meses de edad con vacuna de la varicela, a través de las consultas externas y las hospitalizaciones en el Centro de Referencia Pediátrico de Uruguay. Vacunas. 2005;6:77-81.
108. Quian J, Romero C, Cerisola A, Dalorso P, Rüttiman R, Verstraeten T. Epidemiology of varicella in Uruguay 4 years since the start of universal mass vaccination [abstract no. 110]. 23rd Annual Meeting of the European Society for Pediatric Infectious Diseases. ESPID Valencia (Spain), 18-20 de mayo de 2005.
109. Verstraeten T, Quian J, Rüttiman R. High degree of herd immunity among children of all ages following universal mass vaccination of 12 months old in Uruguay. [abstract no. 116]. 23rd Annual Meeting of the European Society for Pediatric Infectious Diseases. ESPID Valencia (Spain), 18-20 de mayo de 2005.
110. Quian J, Cerisola A, Romero C, Dalorso P, Delfino A, Rüttimann R, et al. Neurologic complications in children hospitalized with varicella before and after the start of the universal mass vaccination of children at the age of 1 year [abstract no. 399]. 23rd Annual Meeting of the European Society for Pediatric Infectious Diseases. ESPID Valencia (Spain), 18-20 de mayo de 2005.
111. Committee on Infectious Diseases of the American Academy of Pediatrics. Recommendations for the use of live attenuated varicella vaccine. Pediatrics. 1995;95:791-6.
112. Guide for Adult Immunization. 3rd ed. Philadelphia: American College of Physicians; 1994.
113. Díez-Domingo J, Gil A, San-Martín M, González A, Esteban J, Baldo JM, et al. Seroprevalence of varicella among children and adolescents in Valencia, Spain. Reliability of the parent's reported history and the medical file for identification of potential candidates for vaccination. Human Vaccines. 2005;1:201-8.
114. Heininger U, Seward JF. Varicella. Lancet. 2006;368:1365-76.
115. Chaves SS, Gargiullo P, Zhang JX, Civen R, Guris D, Mascola L, et al. Loss of vaccine-induced immunity to varicella over time. N Engl J Med. 2007;356:1121-9.
116. Salleras L. Vacunación universal de la población infantil con la vacuna antivaricela atenuada: ¿son necesarias dos dosis de vacuna? Vacunas. 2006;7:141-3.
117. Verstraeten T, Jumaan AO, Mullooly JP, Seward JF, Izurieta HS, DeStefano F, et al. Vaccine Safety Datalink Research Group. A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination. Pediatrics. 2003;112:98e-103e.
118. Watson B. Varicella-zoster vaccine in the USA: success for control of disease severity, but what next? Expert Rev Anti Infect Ther. 2005;3:105-15.
119. Arvin A, Gershon A. Control of varicella: why is a two-dose schedule necessary? Ped Infect Dis J. 2006;25:475-6.
120. Kuter B, Matthews H, Shinefield H, Black S, Dennehy P, Watson B, et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Ped Infect Dis J. 2004;23:132-7.
121. Watson B, Rothstein E, Bernstein H, Arbeter A, Arvin A, Chartrand S, et al. Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization. J Infect Dis. 1995;172:217-9.
122. Vesikari T, Catherine Sadzot-Delvaux C, Bernard Rentier B, Gershon A. Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccine. Pediatr Infect Dis J. 2007;26:632-8.
123. American Academy of Pediatrics. Committee of Infectious Diseases. Prevention of varicella: recommendations for use of varicella vaccines in children, including a recommendation for a routine 2-dose varicella immunization schedulle. Pediatrics. 2007;120:221-31.
124. Oxman MN. Clinical manifestations of herpes zoster. En: Arvin AM, Gershon AA, editors. Varicella zoster virus: virology and clinical management. Cambridge: Cambridge University Press; 2000. p. 246-75.
125. Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract. 1975;25:571-5.
126. Dworkin RH, Portenoy RK. Pain and its persistence in herpes zoster. Pain. 1996;67:241-51.
127. Kost RG, Straus SE. Postherpetic neuralgia: pathogenesis, treatment, and prevention. N Engl J Med. 1996;335:32-42.
128. White CJ. Herpes zoster and quality of life: a self-limited disease with severe impact. Neurology. 1995;45:Suppl 8:52-3.
129. Dworkin RH, Schmader KE. The treatment and prevention of postherpetic neuralgia. Clin Infect Dis. 2003;36:877-82.
130. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect. 2004;4:26-33.
131. Opstelten W, Mauritz JW, De Wit NJ, Van Wijck AJ, Stalman WA, Van Essen GA. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam Pract. 2002;19:471-5.
132. Gershon A, LaRussa P, Steinberg S, Lo SH, Mervish N, Meier P. The protective effect of immunologic boosting against zoster: an analysis in leukemic children who were vaccinated against chickenpox. J Infect Dis. 1996;173:450-3.
133. Brisson M, Edmunds WJ. The cost-effectiveness of varicella vaccination in Canada. Vaccine. 2002;20:1113-25.
134. Feldman S, Hugues WT, Kim HY. Herpes zoster in children with cancer. Am J Dis Child. 1973;126:178-84.
135. Shepp D, Dandliker P, Meyers J. Current therapy of varicella zoster virus infection in immunocompromised patients. Am J Med. 1988;85 Suppl 2A:96-8.
136. Whitley R, Hitly M, Haynes R, Bryson Y, Connor JD, Soong SJ, et al. Vidarabine therapy of varicella in immunosuppressed patients. J Pediatr. 1982;101:125-31.
137. Whitley R, Soong S, Dolin R, Betts R, Linnemann C, Alford C, and the NIAID Collaborative Study Group. Early vidarabine to control the complications of herpes zoster in immunosuppressed patients. N Engl J Med. 1982;307:971-5.
138. Yih WK, Brooks DR, Lett SM, Jumaan AO, Zhang Z, Clements KM, et al. The incidence of varicella and herpes zoster in Massachussets as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. BMC Public Health. 2005;5:68.
139. Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward JF. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis. 2005;191:1999-2001.
140. Berger R, Florent G, Just M. Decrease of the lymphoproliferative response to varicella-zoster virus antigen in the aged. Infect Immunol. 1981;32:24-7.
141. Burke BL, Steele RW, Beard OW, Wood JS, Cain TD, Marmer DJ. Immune response to varicella-zoster in the aged. Arch Intern Med. 1982;142:291-3.
142. Ragozzino MW, Melton LF III, Kurland LT, Chu CP, Perry HO. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore). 1982;61:310-6.
143. Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med. 1995;155:1605-9.
144. Oxman MN. Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurology. 1995;45:Suppl 8:41-6.
145. Levin MJ. Use of varicella vaccines to prevent herpes zoster in older individuals. Arch Virol. 2001;17 Suppl:151-60.
146. Levin MJ, Murray M, Rotbart HA, Zerbe GO, White J, Hayward AR. Immune response of elderly individuals to a live attenuated varicella vaccine. J Infect Dis. 1992;166:253-9.
147. Levin MJ, Barber D, Goldblatt E, Jones M, LaFleur B, Chan C, et al. Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. J Infect Dis. 1998;178:Suppl 1:109-12.
148. Trannoy E, Berger R, Hollander G, Bailleux F, Heimendinger P, Vuillier D, et al. Vaccination of immunocompetent elderly subjects with a live attenuated OKA strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine. 2000;18:1700-6.
149. Redman RL, Nader S, Zernobi L, Liu C, Wong RM, Brown BW, et al. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis. 1997;176:578-85.
150. Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med. 2007;356:1338-43.
151. Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med. 2006;145:317-25.
152. Koplan JP, Harpaz R. Shingles vaccine: effective and costly or cost-effective? Ann Intern Med. 2006;145:386-7.
153. Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis. 2007;44:1280-8.
154. ACIP provisional recommendations for the use of zoster vaccine. Atlanta: Centers for Disease Control and Prevention, 2006 [citado 5 Mar 2007]. Disponible en: http://www.cdc.gov/nip/recs/provisional_recs/zoster-11-20-06.pdf